Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 2, 2014, Pages 185-195

  Hadziyannis, Emilia ^a   Hadziyannis, Stephanos J ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

chronic hepatitis B; hbsag; Hbv; Hbv Dna; inactive carriers; interferon; natural course . Nucleos(t)ide analogs; treatment

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; RECOMBINANT ALPHA INTERFERON; TELBIVUDINE; TENOFOVIR;

ANTIGEN DETECTION; ANTIGEN PRESENTATION; DISEASE COURSE; GENOTYPE; HEPATITIS B; HUMAN; IMMUNOASSAY; IMMUNOASSAY ANALYZER; PREDICTIVE VALUE; PROTEIN SECRETION; PROTEIN SYNTHESIS; QUANTITATIVE ASSAY; REVIEW; SEROCONVERSION; TREATMENT DURATION; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER; TREATMENT OUTCOME;

EID: 84893096212     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.876362     Document Type: Review

References (105)

1. Bonino F, Piratvisuth T, Brunetto MR, Liaw YF. Diagnostic markers of chronic hepatitis B infection and disease. Antivir Ther 2010;15(Suppl 3):35-44
2. Imai M, Tachibana FC, Moritsugu Y, et al. Hepatitis B antigen-Associated deoxyribonucleic acid polymerase activity and e antigen/anti-e system. Infect Immun 1976;14(3):631-5
3. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977;105(2):94-8
4. Skinhoj P. Hepatitis and hepatitis B-Antigen in Greenland. II: occurrence and interrelation of hepatitis B associated surface, core, and e antigen-Antibody systems in a highly endemic area. Am J Epidemiol 1977;105(2):99-106
5. Overby LR, Miller JP, Smith ID, et al. Radioimmunoassay of hepatitis B virus-Associated (Australia) antigen employing 125 I-Antibody. Vox Sang 1973; 24(Suppl):102-13
6. Hadziyannnis S. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Vial Hepatitis Reviews 1995;1(1):7-36
7. Stevens C, Neurath AR, Smuness W, et al. Correlations between HBeAg/anti-HBe, HBsAg titer, HBsAg-Associated albumin binding sites and infectivity. In: Vyas G, Cohen SN, Schmid R, editors. Viral hepatitis. The Franklin Institute Press, Philadelphia, PA, USA; 1978. p. 211-16
8. Shimizu Y, Ida S, Matsukura T, Yuasa T. Determination of hepatitis B virus DNA in serum by molecular hybridization. Microbiol Immunol 1984;28(10):1117-23
9. Nagata I, Colucci G, Gregorio GV, et al. The role of HBV DNA quantitative PCR in monitoring the response to interferon treatment in chronic hepatitis B virus infection. J Hepatol 1999;30(6):965-9
10. Hadziyannis SJ, Vassilopoulos D, Hadziyannis E. The natural course of chronic hepatitis B virus infection and its management. Adv Pharmacol 2013;67: 247-91
11. Brunetto MR, Oliveri F, Colombatto P, et al. Treatment of chronic anti-HBe-positive hepatitis B with interferon-Alpha. J Hepatol 1995; 22(1 Suppl):42-4
12. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34(4 Pt 1):617-24
13. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351(12): 1206-17
14. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352(26): 2682-95
15. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009;136(7):2169-79; e1-4
16. Lau GK. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon. Liver Int 2009; 29(Suppl 1):125-9
17. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49(4): 1141-50
18. Brunetto MR, Marcellin P, Cherubini B, et al. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. J Hepatol 2013; 59(6):1153-9
19. Wong DK, Cheung AM, ORourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-Analysis. Ann Intern Med 1993;119(4):312-23
20. Hadziyannis SJ. Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol 2011;55(1): 183-91
21. Hadziyannis S, Bramou T, Makris A, et al. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. J Hepatol 1990; 11(Suppl 1):S133-6
22. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001;121(1):101-9
23. Brunetto MR, Oliveri F, Colombatto P, et al. Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon. J Hepatol 2003;39(Suppl 1): S164-7
24. Lampertico P, Del Ninno E, Manzin A, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997;26(6): 1621-5
25. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007;12(1):73-82
26. Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32(4 Pt 1): 847-51
27. Moucari R. Peginterferon for chronic hepatitis B: predicting success with on-treatment benchmarks. J Gastroenterol Hepatol 2010;25(9):1474-5
28. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49(4):1151-7
29. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-Alfa. Gastroenterology 2009;137(6):2002-9
30. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010;52(2):454-61
31. Sonneveld MJ, Rijckborst V, Boucher CA, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010;52(4):1251-7
32. Reijnders JG, Rijckborst V, Sonneveld MJ, et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011;54(3):449-54
33. Rodella A, Galli C, Terlenghi L, et al. Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virol 2006; 37(3):206-12
34. Zacher BJ, Moriconi F, Bowden S, et al. Multicenter evaluation of the Elecsys hepatitis B surface antigen quantitative assay. Clin Vaccine Immunol 2011;18(11): 1943-50
35. Short JM, Chen S, Roseman AM, et al. Structure of hepatitis B surface antigen from subviral tubes determined by electron cryomicroscopy. J Mol Biol 2009;390(1): 135-41
36. Locarnini S, Zoulim F. Molecular genetics of HBV infection. Antivir Ther 2010; 15(Suppl 3):3-14
37. Janssen HL, Kerhof-Los CJ, Heijtink RA, Schalm SW. Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy. Antiviral Res 1994;23(3-4):251-7
38. Zoulim F, Mimms L, Floreani M, et al. New assays for quantitative determination of viral markers in management of chronic hepatitis B virus infection. J Clin Microbiol 1992;30(5):1111-19
39. Kohmoto M, Enomoto M, Tamori A, et al. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol 2005;75(2):235-9
40. Dandri M, Murray JM, Lutgehetmann M, et al. Virion half-life in chronic hepatitis B infection is strongly correlated with levels of viremia. Hepatology 2008;48(4):1079-86
41. Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007;5(12): 1462-8
42. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126(7):1750-8
43. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44(3):675-84
44. Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterol 2013;48(1):13-21
45. Shouval D. Focus: quantitative HBsAg measurement as a new surrogate marker for assessment of hepatic fibrosis in HBeAg+ chronic hepatitis B. J Hepatol 2013;58(6): 1063-4
46. Manesis EK, Papatheodoridis GV, Tiniakos DG, et al. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol 2011;55(1):61-8
47. Lee JM, Ahn SH. Quantification of HBsAg: basic virology for clinical practice. World J Gastroenterol 2011;17(3):283-9
48. Chevaliez S, Hezode C, Bahrami S, et al. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/ nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol 2013;58(4): 676-83
49. Locarnini S, Bowden S. Hepatitis B surface antigen quantification: not what it seems on the surface. Hepatology 2012;56(2):411-14
50. Shouval D. Focus. J Hepatol 2013;58(4): 641-2
51. Gehring AJ, Xue SA, Ho ZZ, et al. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol 2011;55(1):103-10
52. Yu H, Hou Z, Han Q, et al. The anti-HBV effect mediated by a novel recombinant eukaryotic expression vector for IFN-Alpha. Virol J 2013;10(1):270
53. Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol 2011;55(5):112131
54. Song EY, Shin Y, Roh EY, et al. Serum HBsAg levels during peginterferon alpha-2a treatment with or without thymosin alpha-1 in HBeAg-positive chronic hepatitis B patients. J Med Virol 2011;83(1):88-94
55. Peng CY, Lai HC, Li YF, et al. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Aliment Pharmacol Ther 2012;35(4):458-68
56. Lee MH, Lee da M, Kim SS, et al. Correlation of serum hepatitis B surface antigen level with response to entecavir in naive patients with chronic hepatitis B. J Med Virol 2011;83(7):1178-86
57. Gramenzi A, Loggi E, Micco L, et al. Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients. J Viral Hepat 2011;18(10):e468-74
58. Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010;139(2): 483-90
59. Seto WK, Liu K, Wong DK, et al. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol 2013;59(4):709-16
60. Seto WK, Wong DK, Fung J, et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 2013;58(3):923-31
61. Seto WK, Wong DK, Fung J, et al. A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology 2012;56(3): 812-19
62. Deguchi M, Yamashita N, Kagita M, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004;115(2):217-22
63. ONeill R, Walsh P, Coen N, et al. Introduction of an auto-dilution for Architect HBsAg quantitative assay. Association for the Study of the Liver Taipei Conference; 2012
64. Sonneveld MJ, Rijckborst V, Boucher CA, et al. A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. J Clin Virol 2011;51(3):175-8
65. Wursthorn K, Jaroszewicz J, Zacher BJ, et al. Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. J Clin Virol 2011;50(4):292-6
66. Park Y, Hong DJ, Shin S, et al. Performance evaluation of new automated hepatitis B viral markers in the clinical laboratory: two quantitative hepatitis B surface antigen assays and an HBV core-related antigen assay. Am J Clin Pathol 2012;137(5):770-7
67. Verheyen J, Neumann-Fraune M, Berg T, et al. The detection of HBsAg mutants expressed in vitro using two different quantitative HBsAg assays. J Clin Virol 2012;54(3):279-81
68. Hadziyannis E. Quantification of HBsAg in serum: characteristics of the assays. OA Hepatology 2013;1(1):1
69. Cento V, Van Hemert F, Neumann-Fraune M, et al. Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen. J Infect 2013;67(4):303-12
70. Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52(4):514-22
71. Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010;52(4): 508-13
72. Kim YJ, Cho HC, Choi MS, et al. The change of the quantitative HBsAg level during the natural course of chronic hepatitis B. Liver Int 2011;31(6):817-23
73. Antaki N, Zeidane N, Alhaj N, et al. HBsAg titers in the different phases of hepatitis B infection in Syrian patients. J Clin Virol 2012;53(1):60-4
74. Martinot-Peignoux M, Asselah T, Marcellin P. HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients. Clin Liver Dis 2013;17(3):399-412
75. Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. The role of HBsAg quantification for monitoring natural history and treatment outcome. Liver Int 2013; 33(Suppl 1):125-32
76. Yan CH, Zhao CY, Ding H, et al. Hepatitis B virus basal core promoter mutations A1762T/G1764A are associated with genotype C and a low serum HBsAg level in chronically-infected HBeAg-positive Chinese patients. Antiviral Res 2012;96(2): 108-14
77. Martinot-Peignoux M, Lapalus M, Laouenan C, et al. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. J Clin Virol 2013; 58(2):401-7
78. Su TH, Liu CJ, Tseng TC, et al. Longitudinal change of HBsAg in HBeAg-negative patients with genotype B or C infection. PLoS ONE 2013;8(2):e55916
79. Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012; 142(5):1140-9.e3; quiz e13-4
80. Chan HL, Wong VW, Chim AM, et al. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther 2010;32(11-12):1323-31
81. Piratvisuth T, Marcellin P, Popescu M, et al. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int 2011; Epub ahead of print
82. Tangkijvanich P, Komolmit P, Mahachai V, et al. Comparison between quantitative hepatitis B surface antigen, hepatitis B e-Antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-Alpha-2b therapy in hepatitis B e-Antigen-positive chronic hepatitis B. Hepatol Res 2010;40(4):269-77
83. Su TH, Liu CJ, Yang HC, et al. Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy. J Gastroenterol 2013; Epub ahead of print
84. Weng M, Zeng WZ, Wu XL, et al. Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposure. Virol J 2013; 10(1):277
85. Ma Q, Qin B, Gong X, Lu X. Prediction of response to interferon alpha-1b in HBeAg-positive chronic hepatitis B: a clue from HBsAg levels. Eur J Gastroenterol Hepatol 2013;25(7):820-4
86. Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 2011;53(6):2121-9
87. Sonneveld MJ, Rijckborst V, Cakaloglu Y, et al. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-Alpha2b: relation to response and HBV genotype. Antivir Ther 2012;17(1):9-17
88. Sonneveld MJ, Hansen BE, Piratvisuth T, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013;58(3): 872-80
89. Sonneveld MJ, Zoutendijk R, Flink HJ, et al. Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response. Clin Infect Dis 2013; 56(1):100-5
90. Rijckborst V, Hansen BE, Ferenci P, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 2012;56(5): 1006-11
91. Gheorghita VI, Caruntu FA, Curescu M, et al. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study. J Gastrointestin Liver Dis 2013;22(1):27-32
92. Lee JM, Ahn SH, Kim HS, et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 2011;53(5):1486-93
93. Wong DK, Seto WK, Fung J, et al. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos (t)ide analogues of different potency. Clin Gastroenterol Hepatol 2013;11(8): 1004-10; e1
94. Fung J, Lai CL, Young J, et al. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol 2011;106(10):1766-73
95. Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010;52(5):1611-20
96. Cai W, Xie Q, An B, et al. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 2010; 48(1):22-6
97. Gish RG, Chang TT, Lai CL, et al. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir. Antivir Ther 2013;18(5):691-8
98. Papatheodoridis G, Goulis J, Manolakopoulos S, et al. Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy. J Hepatol 2013;60(1): 62-8
99. Orito E, Fujiwara K, Kanie H, et al. Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients. World J Gastroenterol 2012; 18(39):5570-5
100. Su CW, Wu CY, Hung HH, et al. Differential roles of serum HBV DNA and HBsAg level in predicting virological breakthrough in patients receiving lamivudine therapy. J Gastroenterol Hepatol 2013;28(12):1849-58
101. Zoutendijk R, Hansen BE, van Vuuren AJ, et al. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis 2011;204(3):415-18
102. Boglione L, DAvolio A, Cariti G, et al. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D. Liver Int 2013; 33(4):580-5
103. Wong GL, Chan HL, Lo AO, et al. Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis e antigen negative chronic hepatitis B patients receiving nucleos(t)ide analogues. Antivir Ther 2013; Epub ahead of print
104. Hadziyannis SJ, Sevastianos V, Rapti I, et al. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012; 143(3):629-36; e1
105. Chan HL, Wong GL, Chim AM, et al. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. Antivir Ther 2011;16(8):1249-57